Back

Assessing outcomes following catheter ablation of ventricular tachycardia in patients with durable left ventricular assist devices

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Outcome after interventions for ventricular arrhythmias Ablation of Ventricular Arrhythmias ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Neal Olarte

University of Miami Leonard M. Miller School of Medicine, Miami (United States of America)

6 More presentations in this session

Presentation thumbnail
Gender disparities in ventricular tachycardia: evaluating clinical outcomes and interventions
Doctor Q. Loyd (Miami, US)
Abstract Slides
Presentation thumbnail
Ventricular tachycardia mechanisms and prevention in patients with severe heart failure and left ventricular assist device
Doctor F. Hohendanner (Berlin, DE)
Abstract Slides
Presentation thumbnail
Bipolar ablation of refractory ventricular arrhythmias using a novel dedicated adapter. A multicenter study.
Associate Professor P. Futyma (Rzeszow, PL)
Abstract Slides
Presentation thumbnail
Sinus rhythm endocardial mapping for channels identification in ischemic ventricular tachycardia using a modified electrophysiological triad
Professor P. Adragao (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Machine learning based risk stratification of patients undergoing ventricular tachycardia ablation
Doctor F. Komlosi (Budapest, HU)
Abstract Slides

Access the full session

Session thumbnail
Outcome after interventions for ventricular arrhythmias

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources